Soligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick Facts

(RTTNews) - Soligenix, Inc. (SNGX) announced a publication describing the preclinical efficacy of CiVax, a thermostabilized subunit vaccine against SARS-CoV-2. In collaboration with Axel Lehrer, Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawai?i at Manoa, the manuscript has been published in COVID.

Using custom-developed immunoassays, the combination of a primary adenovirus vaccine coupled with a CiVax booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series in humans.

For More Such Health News, visit rttnews.com.